In addition, our study of IFIT3 implies its great potential in thyroid cancer progressing which has not been reported yet, and these RBPs especially RPS27L and IFIT3 may also be used in clinical adjuvant therapy. Here, IFIT3 is linked to thyroid gland carcinoma.